Abstracts tagged "interferons and juvenile dermatomyositis"

Abstract Number: 2920 • 2018 ACR/ARHP Annual Meeting
Correlations of Type I Interferon Score and Interferon Induced Chemokines CXCL10 and CXCL9 with Cutaneous and Muscular Disease Activity in Juvenile Dermatomyositis
Gian Marco Moneta¹, Ivan Caiello¹, Lucilla Rava'², Silvia Rosina³, Luisa Bracci Laudiero^1,4, Angelo Ravelli^3,5, Fabrizio De Benedetti⁶ and Rebecca Nicolai⁷, ¹Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, ²Epidemiology Unit, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, ³University of Genova, Genova, Italy, ⁴Institute of Translational Pharmacology, CNR, Roma, Italy, ⁵Rheumatology, Giannina Gaslini Institute, Genova, Italy, ⁶IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, ⁷Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy
Background/Purpose: Interferons (IFNs) seem to play an important role in the pathogenesis of juvenile dermatomyositis (JDM). We previously reported that expression of both type I…
Abstract Number: 2339 • 2017 ACR/ARHP Annual Meeting
Expression of Type I and Type II Interferons Is Increased in Muscle Biopsies of Juvenile Dermatomyositis Patients and Related to Clinical and Histological Features
Rebecca Nicolai¹, Gian Marco Moneta², Silvia Rosina³, Chiara Fiorillo³, Denise Pires Marafon¹, Margherita Verardo⁴, Luisa Bracci Laudiero^5,6, Carlo Minetti^3,7, Angelo Ravelli^3,8 and Fabrizio De Benedetti¹, ¹Division of Rheumatology, IRCCS Bambino Gesù Children's Hospital, Rome, Rome, Italy, ²Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Roma, Italy, ³University of Genova, Genova, Italy, ⁴Unit of Neuromuscular and Neurodegenerative Disorders, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Roma, Italy, ⁵Division of Rheumatology, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Roma, Italy, ⁶Institute of Translational Pharmacology, CNR, Rome, Italy, Rome, Italy, ⁷Pediatric Neurology and Muscular Disorders, Giannina Gaslini Institute, Genova, Italy, ⁸Rheumatology, Giannina Gaslini Institute, Genova, Italy
Background/Purpose: There is growing evidence for an involvement of interferons (IFNs) in the chronic inflammation that characterizes juvenile dermatomyositis (JDM). The aim of this study…
Abstract Number: 2340 • 2017 ACR/ARHP Annual Meeting
Correlation of Type I Interferon Score and CXCL10 (C-X-C Motif Chemokine Ligand 10) with Cutaneous and Muscular Disease Activity in Juvenile Dermatomyositis Patients
Rebecca Nicolai¹, Gian Marco Moneta², Ivan Caiello³, Denise Pires Marafon¹, Silvia Rosina⁴, Luisa Bracci Laudiero^5,6, Angelo Ravelli^4,7 and Fabrizio De Benedetti¹, ¹Division of Rheumatology, IRCCS Bambino Gesù Children's Hospital, Rome, Rome, Italy, ²Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Roma, Italy, ³Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, ⁴University of Genova, Genova, Italy, ⁵Division of Rheumatology, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Roma, Italy, ⁶Institute of Translational Pharmacology, CNR, Rome, Italy, Rome, Italy, ⁷Rheumatology, Giannina Gaslini Institute, Genova, Italy
Background/Purpose: Interferons (IFNs) seem to be important contributors in the pathogenesis of juvenile dermatomyositis (JDM). Our group previously reported that expression of both type I…
Abstract Number: 2103 • 2016 ACR/ARHP Annual Meeting
Peripheral Blood B Cells Are Expanded and Their Cytokine Expression Is Dysregulated in Juvenile Dermatomyositis
Meredyth Wilkinson¹, Christopher Piper², Georg Otto³, Claire Deakin⁴, Stefanie Dowle³, Stefania Simou⁵, Daniel Kelberman³, Yiannis Ioannou⁶, Claudia Mauri⁷, Elizabeth Jury⁸, David Isenberg⁹, Lucy R Wedderburn¹⁰ and Kiran Nistala¹¹, ¹Division of Medicine, University College London, London, United Kingdom, ²Rheumatology, University College London, London, United Kingdom, ³National Institute for Health Research Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom, ⁴Infection, Inflammation and Rheumatology Section,, UCL Institute of Child Health, London, United Kingdom, ⁵Infection, Inflammation and Rheumatology, UCL Institute of Child Health, London, United Kingdom, ⁶Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ⁷Division of Medicine, Centre for Rheumatology Research, University College London, University College London, London, United Kingdom, ⁸Division of Medicine, Centre for Rheumatology Research, University College London, London, United Kingdom, ⁹University College Hospital, London, London, United Kingdom, ¹⁰Infection, Inflammation and Rheumatology Section, UCL Institute of Child Health, London, United Kingdom, ¹¹Centre for Rheumatology, University College London, London, United Kingdom
Background/Purpose: Juvenile dermatomyositis (JDM) is a rare form of childhood autoimmune myositis that presents with proximal muscle weakness and heliotrope rash. B cells are strongly…
Abstract Number: 2423 • 2016 ACR/ARHP Annual Meeting
Differential Interferon Score Expression in the Peripheral Blood in Mendelian Inflammatory Interferonopathies Versus Juvenile Dermatomyositis (JDM) Subtyped By Myositis Autoantibodies and Disease Activity
Hanna Kim¹, Terrance P. O'Hanlon², Adriana Almeida de Jesus³, Yan Huang³, Ira N. Targoff^4,5, Frederick W. Miller², Raphaela Goldbach-Mansky⁶ and Lisa G. Rider², ¹NIAMS/NIH, Bethesda, MD, ²Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ³National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵University of Oklahoma, Oklahoma City, OK, ⁶Translational Autoinflammatory Disease Studies, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD
Background/Purpose: JDM is a complex autoimmune disease with an interferon (IFN) signature, with a reported correlation with disease activity. Clinical features vary among myositis-specific autoantibody…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].